cadillac trial design n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
CADILLAC Trial Design PowerPoint Presentation
Download Presentation
CADILLAC Trial Design

Loading in 2 Seconds...

play fullscreen
1 / 2

CADILLAC Trial Design - PowerPoint PPT Presentation


  • 163 Views
  • Uploaded on

CADILLAC Trial Design. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Combinations Randomized Comparison in the Setting of Acute MI. Age > 18 years Nitrate-unresponsive chest pain consistent with acute MI (duration > 30 min but < 12 hours)

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

CADILLAC Trial Design


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
    Presentation Transcript
    1. CADILLAC Trial Design Controlled Abciximab and Device Investigation to Lower Late Angioplasty Combinations Randomized Comparison in the Setting of Acute MI Age > 18 years Nitrate-unresponsive chest pain consistent with acute MI (duration > 30 min but < 12 hours) Native coronary artery > 2.5 mm, < 4.0 mm Lesion length < 70 mm Stenting (+ abciximab) Balloon angioplasty (+ abciximab) vs Inclusion Criteria

    2. CADILLAC Trial Results Stenting +abciximab(n=525) PTCA +abciximab2(n=528 ) PTCA1,3(n=517 ) Stenting3(n=511 ) TIMI-3 flow 94% 92% 92% 96.7% Recurrent ischemia 4.5% 1.5% 3.9% 1.2% Mortality 1.4% 1.0% 1.6% 1.6% Need for ischemic TVR 2.3% 0.2% 0.8% 0.2% (1) 19.9% provisional stenting; (2) 15.0% provisional stenting; (3) about 5% crossover to abciximab Stone GR, et al. Presented at the AHA 72nd Scientific Sessions. November, 1999.